Scholarlink

Background <p>The biological interaction between human epidermal growth factor receptor 2 (HER2) overexpression and the tumor immune microenvironment (TIME) in urothelial carcinoma (UC) has not been comprehensively elucidated, which limits the rational integration of HER2-targeted therapies with Immune checkpoint Inhibitors (ICIs). This study aimed to characterize the immune landscape associated with HER2 expression and evaluate its clinical implications.</p> Methods <p>Using transcriptomic datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), patients were stratified based on an exploratory threshold, with the highest 20% of ERBB2 mRNA expression defined as HER2-high. Integrated bioinformatic analyses were validated via immunohistochemistry (IHC) in 21 UC specimens. Additionally, a real-world cohort of 29 patients with locally advanced or metastatic UC (la/mUC) treated with disitamab vedotin (RC48), as monotherapy or combined with PD-1 inhibitors, was evaluated for clinical efficacy.</p> Results <p>In this exploratory analysis, HER2-high tumors were associated with an immunologically suppressed phenotype, characterized by reduced immune/stromal infiltration and increased tumor purity. Notably, these tumors exhibited a selective enrichment of FOXP3 + regulatory T cells (Tregs) (<i>P</i> &lt; 0.001) alongside significantly lower expression of canonical immune checkpoints, including CTLA-4, PD-1, and PD-L2 (all <i>P</i> &lt; 0.001). These findings suggest a distinct immune regulatory pattern characterized by regulatory cell enrichment and relatively low expression of classical immune checkpoint molecules.</p> Conclusions <p>HER2 expression in urothelial carcinoma was associated with a distinct immune microenvironmental profile characterized by Treg enrichment and relatively low immune checkpoint expression, as supported by our protein-level validation. These findings provide additional biological context for the potential therapeutic benefit of combining RC48 with ICIs. Given the exploratory nature of the HER2-high definition and the limited sample size of the validation cohorts, further prospective studies are warranted to confirm these observations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of immune microenvironment on immune checkpoint inhibitor response in HER2-overexpressing urothelial carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月18日

查看全文
  • Ruiyang Xia,
  • Meiling Wang,
  • Ning Wang,
  • Yinxu Zhang,
  • Jiahe Zhao,
  • Zhen Wang,
  • Wei Wang,
  • Shuangyan Zheng,
  • Kunxian Huang,
  • Jianshu Dong,
  • Bona Liu,
  • Cheng Du

摘要

Background

The biological interaction between human epidermal growth factor receptor 2 (HER2) overexpression and the tumor immune microenvironment (TIME) in urothelial carcinoma (UC) has not been comprehensively elucidated, which limits the rational integration of HER2-targeted therapies with Immune checkpoint Inhibitors (ICIs). This study aimed to characterize the immune landscape associated with HER2 expression and evaluate its clinical implications.

Methods

Using transcriptomic datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), patients were stratified based on an exploratory threshold, with the highest 20% of ERBB2 mRNA expression defined as HER2-high. Integrated bioinformatic analyses were validated via immunohistochemistry (IHC) in 21 UC specimens. Additionally, a real-world cohort of 29 patients with locally advanced or metastatic UC (la/mUC) treated with disitamab vedotin (RC48), as monotherapy or combined with PD-1 inhibitors, was evaluated for clinical efficacy.

Results

In this exploratory analysis, HER2-high tumors were associated with an immunologically suppressed phenotype, characterized by reduced immune/stromal infiltration and increased tumor purity. Notably, these tumors exhibited a selective enrichment of FOXP3 + regulatory T cells (Tregs) (P < 0.001) alongside significantly lower expression of canonical immune checkpoints, including CTLA-4, PD-1, and PD-L2 (all P < 0.001). These findings suggest a distinct immune regulatory pattern characterized by regulatory cell enrichment and relatively low expression of classical immune checkpoint molecules.

Conclusions

HER2 expression in urothelial carcinoma was associated with a distinct immune microenvironmental profile characterized by Treg enrichment and relatively low immune checkpoint expression, as supported by our protein-level validation. These findings provide additional biological context for the potential therapeutic benefit of combining RC48 with ICIs. Given the exploratory nature of the HER2-high definition and the limited sample size of the validation cohorts, further prospective studies are warranted to confirm these observations.